4DMedical announced it has secured more than US$100 million (AU$150 million) in a new institutional placement to accelerate U.S. growth and expand deployment of its software-based lung imaging technology, led by its FDA-cleared CT:VQ product. The company said the capital will be used to scale adoption across U.S. academic medical centers and health systems, deepen customer enablement and support, and materially increase research and development investment to expand its functional lung imaging portfolio.
CT:VQ is a software-as-a-service offering that generates ventilation and perfusion insights from standard CT imaging, aiming to provide quantified functional information that clinicians can use for diagnosis, treatment planning, and longitudinal monitoring. 4DMedical said that within four months of FDA clearance, CT:VQ was deployed at four major U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health, which the company positioned as early evidence of growing clinical demand for functional respiratory imaging beyond what traditional approaches provide.
Alongside commercial expansion, 4DMedical said it will invest in customer success, training, and technical support so hospitals can integrate CT:VQ into existing clinical workflows and drive consistent utilization at scale. The company also highlighted its intent to use the strengthened balance sheet to increase operational flexibility and support sustained clinical partnerships, including strategic collaborations such as with Philips to broaden adoption pathways.
Following the raise, 4DMedical reported a pro forma cash position exceeding US$130 million (AU$200 million), which it said will support its U.S. rollout strategy and a growing installed base as it seeks to extend its lead in software-based lung imaging.
KEY QUOTES
“This is an extraordinarily important and validating event for multiple reasons. First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”
Andreas Fouras, PhD, Founder and CEO, 4DMedical
